Autoimmune Diseases  >>  Tavalisse (fostamatinib)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

6 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tavalisse (fostamatinib) / Rigel
OSKIRA - 1, NCT01197521 / 2010-020743-12: Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Not Responding.

Checkmark ACR 2016 - OSKIRA - 1
Oct 2016 - Oct 2016: ACR 2016 - OSKIRA - 1
Checkmark Rheumatoid arthritis - ACR/ARHP 2013 (OSKIRA-1)
Sep 2013 - Sep 2013: Rheumatoid arthritis - ACR/ARHP 2013 (OSKIRA-1)
Checkmark OSKIRA-1
More
Completed
3
923
US, Europe, RoW
fostamatinib, placebo, fostamatinib
AstraZeneca
Rheumatoid Arthritis
11/12
11/12
OSKIRA - 3, NCT01197755 / 2010-020745-27: Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Checkmark Rheumatoid arthritis - ACR/ARHP 2013 (OSKIRA-3)
Sep 2013 - Sep 2013: Rheumatoid arthritis - ACR/ARHP 2013 (OSKIRA-3)
Checkmark OSKIRA-3 (TNF-IR study)
Jun 2013 - Jun 2013: OSKIRA-3 (TNF-IR study)
Completed
3
323
US, Canada, Europe, RoW
fostamatinib, placebo
AstraZeneca
Rheumatoid Arthritis
02/13
02/13
OSKIRA - 2, NCT01197534 / 2010-020744-35: Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Disease Modifying Anti-rheumatic Drug (DMARD) But Not Responding.

Checkmark Rheumatoid arthritis - ACR/ARHP 2013 (OSKIRA-2)
Sep 2013 - Sep 2013: Rheumatoid arthritis - ACR/ARHP 2013 (OSKIRA-2)
Checkmark OSKIRA-2
Jun 2013 - Jun 2013: OSKIRA-2
Completed
3
913
US, Canada, Europe, RoW
fostamatinib, placebo, fostamatinib
AstraZeneca
Rheumatoid Arthritis
03/13
03/13
OSKIRA-X, NCT01242514 / 2010-020892-22: Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Terminated
3
1917
Europe, Canada, US, RoW
Fostamatinib
AstraZeneca
Rheumatoid Arthritis
01/15
01/15
NCT02076399 / 2013-005452-15: A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)

Completed
3
76
Canada, US, Europe, RoW
Fostamatinib disodium, R935788, R788, Fostamatinib, Placebo
Rigel Pharmaceuticals
Immune Thrombocytopenic Purpura
04/16
04/16
NCT02076412 / 2013-005453-76: A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)

Completed
3
74
US, Europe, RoW
Fostamatinib Disodium, R935788, R788, Fostamatinib, Placebo
Rigel Pharmaceuticals
Immune Thrombocytopenic Purpura
08/16
08/16

Download Options